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Abstract 
Short communication on t(9;13)(p12;q21) 
PAX5/DACH1, with data on clinics, and the genes 
implicated. 
Clinics and pathology 
Disease 
B-cell acute lymphoblastic leukemia (B-ALL) 
Epidemiology 
Only one case to date, a 5-year old boy with a 
CD10+ ALL (Nebral et al., 2009). 
Prognosis 
The patient was noted at an intermediate risk, 
reached complete remission, and was alive at 23 
months+. 
Genes involved and 
proteins 
PAX5 
Location 
9p13.2 
Protein 
391 amino acids; from N-term to C-term, PAX5 
contains: a paired domain (aa: 16-142); an 
octapeptide (aa: 179-186); a partial homeodomain 
(aa: 228-254); a transactivation domain (aa: 304-
359); and an inhibitory domain (aa: 359-391). 
Lineage-specific transcription factor; recognizes the 
concensus recognition sequence 
GNCCANTGAAGCGTGAC, where N is any  
 
nucleotide.  
Involved in B-cell differentiation.  
Entry of common lymphoid progenitors into the B 
cell lineage depends on E2A, EBF1, and PAX5; 
activates B-cell specific genes and repress genes 
involved in other lineage commitments.  
Activates the surface cell receptor CD19 and 
repress FLT3.  
Pax5 physically interacts with the RAG1/RAG2 
complex, and removes the inhibitory signal of the 
lysine-9-methylated histone H3, and induces V-to-
DJ rearrangements.  
Genes repressed by PAX5 expression in early B 
cells are restored in their function in mature B cells 
and plasma cells, and PAX5 repressed (Fuxa et al., 
2004; Johnson et al., 2004; Zhang et al., 2006; 
Cobaleda et al., 2007; Medvedovic et al., 2011). 
DACH1 
Location 
13q21.33 
DNA/RNA 
2 splice transcript variants. 
Protein 
708 and 760 amino acids (aa). From N-term to C-
term (for the 760 aa form), contains a Poly-Ala (aa 
61-68), three Poly-Gly (aa 74-89; aa 92-103; aa 
116-123), a Poly-Ser (aa 142-165), a Dachshund 
domain motif N (aa 191-277), an interaction region 
with SIX6 (14q23.1) and HDAC3 (5q31) (aa 191-
386), two Poly-Ala (aa 327-335; aa 469-472), a 
Dachshund Domain motif C (aa 618-698), an 
interaction region with SIN3A (15q24.2) and 
SIN3B (19p13.11),(aa 629-708), and a Coiled coil 
domain (aa 632-720) (Swiss-Prot). 
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PAX5/DACH1 fusion protein. 
 
DACH1 is a tumor suppressor. DACH1 
downregulates EGFR (7p11.2), CCND1 (11q13), 
ESR1 (6q25.1) and AR (Xq12), and also TGFB1 
(19q13.2), through interaction with SMAD4 
(18q21.2) and NCOR1 (17p11.2). DACH1 
coprecipitates the histone deacetylase proteins 
(HDAC1, HDAC2, and NCOR1). DACH1 
transcriptionally represses JUN (1p32.1), and FOS 
(14q24.3), and DACH1 inhibits DNA synthesis and 
cellular proliferation (Wu et al., 2007).  
DACH1 is involved in the PAX-EYA-SIX-DACH 
regulatory pathway (eyeless (PAX6), sine oculis 
(SIX1, SIX2, SIX3, SIX4, SIX5, SIX6), eyes 
absent (EYA1, EYA2, EYA3, EYA4), and 
dachshund (DACH1-2)). CREBBP (16p13.3) is 
involved in this process. 
DACH1 is involved in the development of the 
neocortex and the hippocampus, is expressed by 
neural stem cells during early neurogenesis, and 
also in adult neurogenesis following brain ischemia 
(Honsa et al., 2013). DACH1 inhibits breast cancer 
cellular proliferation via cyclin D1 (Nan et al., 
2009). DACH1 suppresses epithelial-mesenchymal 
transition via repression of cytoplasmic 
translational induction of SNAI2 (8q11.21) by 
inactivating YBX1 (1p34.2). DACH1 blockes 
YBX1-induced mammary tumor growth (Wu et al., 
2014). DACH1 expression appears to be predictive 
of good prognosis in oestrogen receptor (ER) 
positive breast cancer (Powe et al., 2014). DACH1 
inhibites prostate cancer cellular DNA synthesis 
and growth (Wu et al., 2009). DACH1, BMP7 
(20q13.31), and MECOM (EVI1, 3q26.2) were up- 
regulated in advanced-stage ovarian cancers, and 
inhibited TGF-beta signaling in these cancers 
associated with TGFb resistance (Purcell et al., 
2005).  
DACH1 is frequently methylated in hepatocellular 
carcinoma and DACH1 expression is regulated by 
promoter hypermethylation.  
Down-regulation of DACH1 is a novel mechanism 
for gaining resistance to the TGFB1 (19q13.2) 
antiproliferative signaling (Zhu et al., 2013). 
DACH1 is also frequently methylated in human 
colorectal cancer and methylation of DACH1 may 
serve as detective and prognostic marker in 
colorectal cancer (Yan et al., 2013). DACH1 
regulates FGF2 (4q27)-mediated tumor-initiating 
activity of glioma cells and inhibits formation of 
tumor-initiating spheroids of glioma cells 
(Watanabe et al., 2011). 
Result of the chromosomal 
anomaly 
Hybrid gene 
Description 
Fusion of PAX5 exon 5 to DACH1 exon 5. 
Fusion protein 
Description 
585 amino acids. The predicted fusion protein 
contains the DNA binding paired domain of PAX5 
(the 201 N-term aa) and the DACHbox-C of 
DACH1 (the 384 C-term aa). 
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